introduction around two percent general population carry pathogenic variant susceptibility gene breast cancer and/or ovarian cancer bc/oc carrier pvs bc/oc susceptibility gene benefit targeted intervention depending personal risk profile increased surveillance risk-reducing surgery comprehensive genetic testing remains costly however guidance required identify individual offer screening pvs year multiple algorithm developed predict likelihood carrying brca1 brca2 breast ovarian analysis disease incidence carrier estimation algorithm boadicea widely used breast cancer risk assessment tool european genetics clinic validity predict likelihood pvs brca1 brca2 demonstrated several large-scale study latest implementation part canrisk suite bc/oc risk prediction model model expanded include palb2 chek2 atm bard1 rad51c rad51d make boadicea comprehensive model available predict likelihood pvs bc/oc susceptibility gene yet performance predict pvs gene brca1 brca2 remains evaluated independent cohort study validated performance two thousand individual examined germline pvs bc/oc susceptibility gene clinical genetics department denmark method ethic declaration study conducted accordance declaration helsinki method involving human participant data performed following relevant guideline regulation research ethic committee system denmark consisted local institutional review board national committee health research ethic denmark national committee authority waive requirement informed consent study included comprehensive genetic information participant however ethic approval deemed unnecessary committee reference legislation registry-based study since data generated clinical setting ref denmark requirement consent participant ethic approval waived law registry-based study accordance danish data protection legislation study registered region southern denmark ref 19/29487 danish patient safety authority granted permission study medical record ref 3-3013-3247/1 study population study population identified registry clinical genetics laboratory odense university hospital performed next generation sequencing 64-gene panel clinical testing pvs brca1 brca2 period january december patient sample originated two geographic area odense university hospital region southern denmark 1.2 million inhabitant aarhus university hospital central denmark region 1.3 million inhabitant genetic testing bc/oc susceptibility offered public hospital free charge guided national referral criterion danish breast cancer cooperative group identify individual high-risk family genetic testing preferentially offered affected individual secondarily nearest related relative supplementary table department adhere criterion however genetic testing could also offered according clinical decision inclusion criterion study availability next generation sequencing data meeting sequencing quality criterion identified pedigree clinical genetics department sample origin data source pedigree pre-test counselling genetics professional recorded pedigree patient family history general rule included least three generation tracing back patient pedigree record included source information vital status date birth age cancer history family member cancer diagnosis validated medical record family member wherever possible genetic work-up would result high validation rate cancer diagnosis study pedigree collected pedigree data bank include three-generation family history patient full sibling parent grandparent aunt uncle cancer diagnosis included data bank regardless source information pedigree data bank contained following record sex familial relation year birth age vital status age breast cancer bilateral breast cancer ovarian cancer including cancer ovary fallopian tube primary peritoneal cancer prostate cancer pancreatic cancer breast cancer subtype expression pattern estrogen receptor human epidermal receptor her2 progesterone receptor expression routinely evaluated denmark instead progesterone receptor expression assumed correspond estrogen receptor expression information breast cancer expression cytokeratin cytokeratin 5/6 unavailable therefore included study male breast cancer assumed unilateral missing subtype accordance model pathology information linkage personal identification number proband available record obtained danish pathology data bank detailed registry specimen analyzed pathology laboratory denmark first record registry span registry incomplete registry became nationwide registry danish version systemized nomenclature medicine code officially updated version available website www.patobank.dk record registry must contain least one topography code morphology code addition record may contain code etiology function disease procedure denote additional information origin hormone receptor status etc diagnosis cancer identified basis primary cancer topography interest direct invasion metastasis origin interest origin unspecified direct invasion metastasis ovarian cancer assumed case serous carcinoma breast cancer case invasive ductal lobular carcinoma situ cancer excluded information receptor expression deemed valid date specimen within one year diagnosis breast cancer pathogenic variant sample preparation next generation sequencing performed using dna agilent sureselectxt reagent kit custom designed adaptor target enrichment performed using custom 64-gene sureselextxt panel designed lund university hospital panel designed aim even coverage includes intron brca1 brca2 sequencing performed using sequencing sample illumina nextseq high output flow cell minimum coverage aimed region required meet sequencing quality criterion typical mean coverage data alignment small variant calling processed using illumina dragen bio-it platform illumina san diego u.s. sequencing data aligned human genome reference grch37 vcf file small variant imported varseq golden helix bozeman u.s. annotation variant annotated using refseq transcript filtered dragen quality coverage population frequency variant within coding region padding evaluated copy-number variant cnvs called varseq cnv caller golden helix bozeman u.s. whole exon used target region cnv calling clinical significance small variant cnvs evaluated manually gene specific acmg guideline clingen including expert panel enigma http applied variant classification class likely pathogenic class pathogenic variant considered pvs evaluation boadicea included pvs brca1 brca2 palb2 chek2 atm bard1 rad51c rad51d brca1 brca2 variant type included also missense pvs remaining gene predicted truncating variant included accordance boadicea model action taken blind assessment data analysis sample size study determined available data predicted carrier likelihood pvs brca1 brca2 palb2 chek2 atm bard1 rad51c rad51d obtained boadicea v6.1.0 analysis pedigree canrisk server http pedigree included proband family member 2nd degree relative including year birth age death cancer history breast cancer subtype described previous section predictor included known age individual time genetic test result polygenic risk score multifactorial risk factor included cytokeratin cytokeratin 5/6 action taken blind assessment predictor boadicea default setting pvs mut_freq population-specific cancer incidence rate denmark used cancer_rates denmark sensitivity analysis performed setting default value mut_freq cancer_rates boadicea requires year birth age age diagnosis individual included model data validation imputation missing data variable performed described supplement see supplementary method result whole study population data imputation compared complete-case analysis individual complete information imputed variable accuracy predicted likelihood investigated term calibration discrimination boadicea calibration model evaluated observed-to-expected ratio o/e compared observed number carrier pathogenic variant expected number carrier pathogenic variant expected number carrier determined summation predicted likelihood assuming sensitivity genetic testing ass impact assuming reduced sensitivity genetic testing predicted carrier likelihood multiplied current canrisk default sensitivity boadicea model assuming cnv analysis performed gene case sensitivity genetic testing assumed reduced due unclassified missense pvs brca1 sensitivity brca2 sensitivity examine calibration model across spectrum carrier probability individual stratified different category combined predicted likelihood gene evaluated confidence interval o/e ratio derived uncertainty estimation observed number assuming expected number given without error two-sided confidence interval o/e ratio hence calculated upper lower bound exact binomial confidence interval observed number calibration plot constructed stata module pmcalplot defined category predicted likelihood gene combined five equally sized quantiles predicted likelihood individual gene statistical evidence deviation optimal calibration evaluated hosmer–lemeshow test using predicted probability boadicea implemented stata module discriminative ability model evaluated area receiver operating characteristic roc curve auc compare sensitivity specificity model range auc 0.5 apparent accuracy 1.0 perfect accuracy predictive model auc two-sided confidence interval estimated using delong method sensitivity specificity model reported potentially clinically relevant threshold carrier probability data analysis performed stata v17.0 statacorp usa result validation study included 2,033 individual tested pvs bc/oc susceptibility gene counselling clinical genetics department denmark table table demographic data study cohort full size table calibration evaluate calibration boadicea compared observed number carrier pvs cohort expected number model boadicea accurately predicted combined likelihood carrying pvs gene brca1 brca2 palb2 chek2 atm bard1 rad51c rad51d thus ratio observed expected carrier gene combined 1.11 0.97–1.26 using default setting cancer incidence rate instead population-specific incidence rate denmark yielded similar result overall o/e 1.07 0.94–1.22 model remained largely well-calibrated different category predicted likelihood moderate departure unity lowest highest carrier probability evident calibration plot fig table miscalibration statistically significant hosmer–lemeshow 0.001 figure calibration plot corresponds table show expected observed likelihood according category predicted carrier probability brca1 brca2 palb2 chek2 atm bard1 rad51c rad51d dashed line corresponds model optimal calibration spike green show observed likelihood full size image table calibration according predicted likelihood carrying brca1 brca2 palb2 chek2 atm bard1 rad51c rad51d full size table stratified analysis model underestimated combined likelihood pvs brca1 brca2 o/e 1.38 1.17–1.61 overestimated likelihood gene model o/e 0.78 0.60–0.99 sub-analyses trend towards underestimating likelihood pvs increasing carrier probability supplementary table however statistical evidence miscalibration brca1 brca2 hosmer–lemeshow 0.001 gene model cut-offs predicted carrier probability 0.13 assessing calibration quantiles predicted likelihood yielded similar result supplementary fig model remained broadly well-calibrated regardless clinical data proband slightly better calibrated individual cancer diagnosis o/e 1.06 0.92–1.22 unaffected individual o/e 1.48 1.02–2.07 model overestimated likelihood carrying pvs individual personal family history bilateral breast cancer likewise underestimated likelihood individual personal family history ovarian cancer somewhat supplementary table also assessed impact assuming reduced sensitivity genetic testing due unclassified missense pvs brca1 brca2 assumption ratio observed expected carrier 1.16 1.01–1.32 indicating model remain largely well-calibrated improvement classification missense variant discrimination receiver-operating characteristic model indicated acceptable overall discrimination carrier non-carriers pvs auc 0.70 0.66–0.74 auc gene combined slightly lower discrimination reported validation study previous version boadicea included brca1 brca2 e.g however discrimination boadicea better brca1 brca2 auc 0.79 0.75–0.83 gene model auc 0.59 0.52–0.66 fig likewise evaluation predictive performance model individual cut-offs carrier probability showed higher sensitivity specificity predicting carrier pvs brca1 brca2 compared gene model table figure receiver-operating characteristic boadicea dashed line corresponds model ability discriminate carrier non-carriers pvs area roc curve 0.5 top graph gene model middle graph brca1 brca2 bottom graph gene model palb2 chek2 atm bard1 rad51c rad51d full size image table performance boadicea different carrier probability cut-offs identifying carrier brca1 brca2 palb2 chek2 atm bard1 rad51c rad51d full size table discrimination boadicea vary much clinical data proband showing improvement clinical condition strongly associated pvs brca1 gene ovarian cancer her2 negative breast cancer supplementary table individual gene overall level model well-calibrated brca2 chek2 atm significantly pvs expected detected brca1 pvs expected palb2 notably four individual detected pvs palb2 compared twenty expected carrier study insufficiently powered validate predicted likelihood carrying rare pvs rad51c rad51d bard1 table table calibration individual gene full size table statistical evidence sub-optimal calibration brca1 hosmer–lemeshow 0.001 brca2 0.001 showed underestimation low predicted likelihood overestimation high predicted likelihood similar result overall model two gene combined evidence mis-calibration chek2 0.98 atm 0.70 caveat fewer observation term discrimination auc brca1 0.83 0.78–0.87 brca2 0.76 0.68–0.83 chek2 0.68 0.60–0.76 atm 0.62 0.48–0.76 calibration plot roc curve gene provided supplement supplementary fig remaining gene observation analysis missing information completeness data high probands family however information missing least one family member completeness data lower region southern denmark 3.0 central denmark region 15.7 complete-case analysis 9.2 family complete year birth age death age cancer information family member trend towards underestimating likelihood carrying compared study population whole trend found complete-case analysis year birth information age death age cancer information isolated supplementary table later discussed complete-case analysis could suggest year birth information likely complete family detected case family member would offered genetic counselling testing known sensitivity analysis included carrier status proband predictor imputation missing data family significantly alter calibration o/e 1.11 0.97–1.26 discrimination model auc 0.71 0.66–0.75 discussion previous study demonstrated boadicea earlier version highly accurate predicting likelihood carrying pvs brca1 brca2 discrimination model brca1 brca2 present evaluation identical reported largest study date present study confirms boadicea remains well-calibrated addition palb2 chek2 atm bard1 rad51c rad51d also establishes model remains significantly better chance discriminate carrier non-carriers pvs bc/oc susceptibility gene chek2 pvs add moderately risk bc/oc notably discrimination model significantly better brca1 brca2 gene model reduced ability discriminate carrier non-carriers pvs gene necessarily reflect poor optimization model however lower auc would expected given lower penetrance pvs gene compared brca1 brca2 since performance earlier version boadicea broadly similar european country expect result present study likely applicable european population although notable difference population frequency pvs could affect result frequent chek2 1100delc accuracy boadicea non-european population studied however tailored model may needed improve accuracy predicted likelihood individual non-european ancestry development data first version boadicea based multiple family study meta-analysis non-uk cohort including high-risk population-based case later version made specific population including danish population-specific cancer incidence rate therefore population development validation data could assumed broadly comparable although comparison baseline characteristic different cohort could made overall level good correspondence observed expected carrier pvs across different magnitude predicted likelihood yet individual predicted likelihood five ten percent observed frequency pvs higher predicted model although magnitude difference unlikely significance genetic counselling may importance consider weighing cost benefit offering genetic testing population according given threshold predicted likelihood decreasing cost genetic testing could argued usefulness prediction model ass likelihood carrying diminish time however somewhat contradicted continued release new prediction model alongside update existing model boadicea brcapro time show future respective need prediction model high- low-income country whereas calibration boadicea largely unaffected clinical data individual model tended overestimate likelihood carrying pvs individual personal family history bilateral breast cancer underestimate likelihood individual history ovarian cancer however affect ability model discriminate carrier non-carriers pvs good condition moreover deviation model calibration could population-specific would need confirmed population note new risk prediction model ovarian cancer already incorporated canrisk risk prediction model contralateral breast cancer risk underway since gene panel testing becoming increasingly widespread matter clinical setting likely overall carrier probability however could vary depending local guideline available resource gene-level boadicea slightly underestimated likelihood carrying pvs brca1 well-calibrated brca2 underestimation pvs brca1 previously reported continental europe compared united kingdom may reflect difference population frequency pvs interestingly also found model overestimate likelihood pvs palb2 present study population indicates pvs represent relatively rare cause bc/oc susceptibility denmark suggests population frequency pvs palb2 may somewhat different denmark compared assumed canrisk hand cancer risk associated pvs palb2 becoming similar brca1 brca2 thus interesting three gene considered jointly difference observed expected count pvs would decrease present study population model well-calibrated remaining gene pvs prevalent individual bc/oc brca2 chek2 atm bard1 rad51c rad51d pvs rare validate model confidence though model appeared well-calibrated bard1 well sensitivity genetic testing needed considered evaluating accuracy boadicea predicts likelihood carrying rather likelihood detecting parameterizing boadicea based estimated penetrance population frequency pvs previous study developer model assumed sensitivity detection reduced study due unclassified missense pvs brca1 brca2 lack cnv analysis remaining gene model includes protein-truncating pvs prevalence unclassified missense pvs brca1 brca2 estimated frequency rare variant large case–control study sensitivity included canrisk default option estimate likelihood carrying following negative search pvs present study included cnv analysis gene assumption sensitivity genetic testing agreement parameterization boadicea chek2 atm palb2 bard1 rad51c rad51d whereas would reasonable evaluation model assume reduced sensitivity genetic testing brca1 brca2 unclassified missense pvs would also missed evaluation data set yet assuming reduced sensitivity genetic testing brca1 brca2 corresponding estimated contribution unclassified missense pvs gene significantly affect observed calibration model indicating model remain well-calibrated improvement classification missense variant prevalence non-coding pvs brca1 brca2 unknown loss sensitivity due failure detect example deep intronic variant thought low also worth emphasizing included class class variant category pathogenic although class variant 0.90–0.99 probability pathogenic variant would also used predictive testing denmark hence inclusion variant validation data set reflected standard clinical practice important note ascertainment patient present study population may limit generalizability finding patient included specialized clinical genetics department result high-risk setting may necessarily applicable population-based setting like primary care study limitation like study make use pedigree information collected clinical setting information missing pedigree member access national pathology database possibility link record proband using central person register denmark completeness data high patient underwent genetic testing case would assume data missing random allow imputation univariable multivariable regression model complete-case analysis suggested information missing completely random hence observed calibration differed study population whole individual complete information importantly however calibration would appear differ missing information year birth missing information age death age cancer possibly information year birth likely recorded family detected additional family member would offered predictive testing family worthy notice doe necessarily imply violation missing random hypothesis missing information could reliably predicted available data given included known year birth family member imputation missing random hypothesis appears plausible model supported fact including carrier status pvs proband imputation missing data significantly affect result moreover year birth little effect estimated carrier probability compared age death age cancer boadicea altogether since nearly complete information available vast majority individual bias violation missing random assumption likely limited notably even missing information model could discriminate carrier non-carriers pvs observable difference study population whole complete-case analysis data completeness also differed two department likely reflected difference clinical practice two department using danish civil registration system complete information year birth age death family member difference unlikely affected result present study another limitation study inability adjust family clustering individual originated family could led slight overestimation observed expected ratio searching pvs additional family member would cease detected one however assumed bias limited since testing pvs would generally occur parallel relevant family member furthermore brca1 brca2 gene reported clinically analyzed real-time study period whereas palb2 rad51c rad51d entered end study thus pvs gene brca1 brca2 would followed clinical genetics department rule pedigree member may tested pvs study non-participating center possible pedigree meet outlined genetic testing criterion decision offer genetic testing could also made clinical geneticist ground example family history deemed uninformative due lack contact unfortunately know extent family-based criterion meant also individual could eligible genetic testing relation another family member meeting testing criterion also collect data risk-reducing surgery cohort family uptake risk-reducing surgery previously reported relatively high family hereditary bc/oc susceptibility denmark yet potential bias previous testing following individual longer risk bc/oc unlikely large majority patient tested pvs shortly diagnosis cancer also information risk-reducing surgery family member may necessarily available clinic due case present study evaluate male breast cancer separately validation study focused group patient previously demonstrated acceptable performance model brca1 brca2 multifactorial risk factor polygenic risk score included present validation could potentially improve performance model finally usefulness including cytokeratin cytokeratin 5/6 expression prediction identify breast cancer basal-like phenotype need evaluated information available despite limitation finding indicate boadicea remains valid decision-making aid determining cost-effective manner individual offer genetic testing pvs susceptibility gene bc/oc furthermore study suggests model well-calibrated moderate penetrance gene chek2 atm may implication validity cancer risk prediction future large-scale prospective study healthy carrier pvs gene needed confirm validity predicted cancer risk similar previous validation study family history polygenic risk score yet interesting recent evaluation boadicea version suggests high accuracy cancer risk associated pvs jointly gene model conclusion study confirms boadicea remains valid decision-making aid determining individual offer genetic testing pvs bc/oc susceptibility gene expansion model include effect protein-truncating pvs chek2 atm palb2 bard1 rad51c rad51d calibration optimal predicted carrier probability around ten twenty percent however evidence underestimation lower carrier probability overestimation higher carrier probability discrimination significantly better brca1 brca2 jointly gene model individual gene study confirms previous report underestimation brca1 population including denmark significant overestimation palb2 could population-specific need confirmed population study insufficiently powered validate prediction rarest pvs bard1 rad51c rad51d altogether question remain clinical usefulness prediction individual gene